Updates are available Correction dated 2022-11-03
Click to view Correction: https://doi.org/10.1186/s13024-022-00573-5
Updates are available Correction dated 2024-03-22
Click to view Correction: https://doi.org/10.1186/s13024-024-00716-w
-
Authors
Ma, Qingyi
Zhao, Zhen
Sagare, Abhay P
Wu, Yingxi
Wang, Min
Owens, Nelly Chuqui
Verghese, Philip B
Herz, Joachim
Holtzman, David M
Zlokovic, Berislav V
-
Funding
Funding for this research was provided by:
National Institutes of Health (R01NS034467, R01AG023084, R01AG039452)
- License Information
-
More Information
Article History
Received: 30 August 2018
Accepted: 1 October 2018
First Online: 19 October 2018
Change Date: 22 March 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13024-024-00716-w
Change Date: 3 November 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13024-022-00573-5
Ethics approval and consent to participate
: The animal experiments were approved by the Institutional Animal Care and Use Committee at the University of Southern California with National Institutes of Health guidelines.
: Not applicable.
: DMH is an inventor on a patent filed by Washington University on the topic of anti-apoE antibodies that was licensed by Denali. DMH co-founded and is on the scientific advisory board of C<sub>2</sub>N Diagnostics. DMH consults for Genentech, AbbVie, Eli Lilly, Proclara, and Denali. Washington University receives research grants to the lab of DMH from C2N Diagnostics, AbbVie, and Denali. PBV, is a full-time employee of C2N Diagnostics, receiving stock and/or stock options.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
